These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 17608887)

  • 61. PBMs to the rescue? Pharmacy benefit managers will play a key role in the Medicare drug benefit. What does it mean for the industry, consumers and Uncle Sam?
    Fong T
    Mod Healthc; 2005 Nov; 35(48):26-8, 30. PubMed ID: 16617721
    [No Abstract]   [Full Text] [Related]  

  • 62. Drugs, debates, deals, and deficits.
    Scott JS
    Healthc Financ Manage; 2002 Dec; 56(12):30, 33. PubMed ID: 12516156
    [No Abstract]   [Full Text] [Related]  

  • 63. Best medicines for less: we compare drugs for what ails America.
    Consum Rep; 2008 Jan; 73(1):27-9. PubMed ID: 18488284
    [No Abstract]   [Full Text] [Related]  

  • 64. The Medicare Modernization Act of 2003, part D.
    Simonson W
    J Am Med Dir Assoc; 2005; 6(3):231-2. PubMed ID: 15894257
    [No Abstract]   [Full Text] [Related]  

  • 65. E-prescribing and Part D drugs.
    Davino MM
    Med Econ; 2006 Feb; 83(3):26. PubMed ID: 16506623
    [No Abstract]   [Full Text] [Related]  

  • 66. What's the benefit? A new federal Medicare drug plan stimulates independent actions and new ideas, but what's the future role for states?
    Cauchi R
    State Legis; 2004; 30(7):28-33. PubMed ID: 15241878
    [No Abstract]   [Full Text] [Related]  

  • 67. Out-of-pocket costs to users: medicine options for hypertension.
    Arredondo A
    Am J Hypertens; 2008 May; 21(5):492. PubMed ID: 18437138
    [No Abstract]   [Full Text] [Related]  

  • 68. Pharmaceuticals: pharmaceutical cost controls.
    Seay M; Lee LL
    Issue Brief Health Policy Track Serv; 2007 Jan; ():1-22. PubMed ID: 17357250
    [No Abstract]   [Full Text] [Related]  

  • 69. Saving money on prescription drugs.
    Meadows M
    FDA Consum; 2005; 39(5):18-26. PubMed ID: 16419288
    [No Abstract]   [Full Text] [Related]  

  • 70. In Beltway, all eyes are on drug benefit.
    Gardner J
    Mod Healthc; 2000 May; 30(21):44. PubMed ID: 11067548
    [No Abstract]   [Full Text] [Related]  

  • 71. PBMs' rebate income threatened by lawsuits and move to generics.
    Sipkoff M
    Manag Care; 2008 Mar; 17(3):11-2. PubMed ID: 18447152
    [No Abstract]   [Full Text] [Related]  

  • 72. A few specialty drug prices fall--all generics.
    Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766
    [No Abstract]   [Full Text] [Related]  

  • 73. Medicare prescription drug coverage (part D): challenges and opportunities.
    Witten B
    Nephrol News Issues; 2006 Aug; 20(9):14-6, 18. PubMed ID: 16916055
    [No Abstract]   [Full Text] [Related]  

  • 74. Overview of Medicare Part D prescription drug benefit: potential implications for patients with psychotic disorders.
    Rosenberg JM
    Am J Health Syst Pharm; 2007 Jan; 64(2 Suppl 1):S18-23; quiz S24-5. PubMed ID: 17215472
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Valuable information regarding generic drugs. Cutting costs by going generic.
    J Am Vet Med Assoc; 2004 Oct; 225(8):1168. PubMed ID: 15521435
    [No Abstract]   [Full Text] [Related]  

  • 76. To cut costs, risky drug use.
    Consum Rep; 2011 Nov; 76(11):9. PubMed ID: 22022754
    [No Abstract]   [Full Text] [Related]  

  • 77. Catastrophic health insurance: budget and policy issues.
    Helms RB
    Am J Pharm Educ; 1989; 53(4):356-9. PubMed ID: 10304253
    [No Abstract]   [Full Text] [Related]  

  • 78. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.
    Sinha MS; Curfman GD; Carrier MA
    JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104
    [No Abstract]   [Full Text] [Related]  

  • 79. Patients who pay out-of-pocket receive lower-cost drugs.
    Am J Health Syst Pharm; 1998 Aug; 55(15):1556-8. PubMed ID: 9706178
    [No Abstract]   [Full Text] [Related]  

  • 80. Medicine and the pharmaceutical industry: what's right, what's wrong, and what's to come.
    Tan SY
    Singapore Med J; 1998 Mar; 39(3):91-5. PubMed ID: 9632964
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.